Allergy’s lesson: don’t bet on studies that have been delayed
The long overdue readout of a pivotal birch pollen allergy vaccine trial draws a blank for the beleaguered UK company.
Upcoming events – Allergy's long-awaited birch data and Caladrius's Treg test
Allergy Therapeutics awaits twice-delayed phase III data on its birch pollen project, while Caladrius Biosciences seeks validation of its Treg approach to type 1…
Upcoming events – FDA decision for Progenics and Allergy comes out of hiding
Progenics hopes to secure US approval for Azedra, while Allergy Therapeutics awaits phase III data with its birch vaccine.
